

Valemetostat Tosilate: Adis Evaluation

Key Points

- A selective dual inhibitor of EZH1/2 that is being developed by Daiichi Sankyo for the treatment of various haematological malignancies and solid tumours
- Received its first approval on 26 September 2022 in Japan
- Approved for the treatment of patients with R/R ATL

Summary

Valemetostat tosilate (valemetostat; EZHARMIA®), a selective dual inhibitor of histone-lysine N-methyltransferases enhancer of zeste homolog 1 and 2 (EZH1/2), is being developed by Daiichi Sankyo Company, Ltd for the treatment of various haematological malignancies and solid tumours, including types of non-Hodgkin lymphomas (NHL).

Valemetostat was approved in Japan in September 2022 for the treatment of patients with relapsed or refractory adult T-cell leukaemia/lymphoma (R/R ATL), a subtype of NHL.

This summary represents the opinions of the [author/authors]. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online. © Springer Nature Switzerland AG 2022.